In September, Canadian Nuclear Laboratories (CNL) and Triumf announced they were teaming up on the commercial production of what’s been called “the rarest drug on earth.” Actinium-225 is an alpha-emitting isotope with a short half-life that can be combined with a protein or antibody that specifically targets cancer cells. It has shown promise in experimental uses on late stage cancer patients to kills cancer cells. Each year, the entire world only makes an amount equal to the weight of a few grains of sand. The TRIUMF cyclotron centre in Vancouver had been discarding substantial amounts of Ac-225 for years, unaware […] Read more about Nuclear researchers produce the rarest drug on Earth